Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer 2024-12-12 18:07
Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services 2024-12-12 17:30
Waterdrop Inc. Announces Third Quarter 2024 Unaudited Financial Results, Net profit rises 152.6% year-on-year 2024-12-12 16:13
CBC Group R-Bridge Healthcare Fund Announces up to US$50 Million Financing for Human Investments Ltd. to Fund Motiva® Market Expansion 2024-12-12 14:14
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients 2024-12-12 11:48
QNET Stands in Solidarity with Cambodia and the World for a Mine-Free Future 2024-12-12 01:34
THERME GROUP ACQUIRES THERME ERDING AND SECURES €320 MILLION FINANCING, TO CREATE THE WORLD'S LARGEST WELLBEING INFRASTRUCTURE PLATFORM 2024-12-12 00:03
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™ 2024-12-11 23:15
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion 2024-12-11 14:44
Call for Application for 2025 Tsinghua Amgen Scholars Program 2024-12-11 14:33
2024 PHBS-CJBS Global Pitch Competition Grand Final Held 2024-12-11 12:29
AXA and HKBN Deepen Collaboration with Launch of "HKBN SmartTraveller Plus" 2024-12-11 11:52
Partnership Established to Advance WHO's Road Map for Neglected Tropical Diseases 2021-2030 2024-12-11 09:00
Community Med Care's " Uplift with Love - Angel Mission" 6th Anniversary 2024-12-11 09:00
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months 2024-12-10 22:31
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety 2024-12-10 22:20
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib 2024-12-10 21:34
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax 2024-12-10 21:30
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report 2024-12-10 21:27
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL 2024-12-10 20:48
1 8 9 10 11 12 812